The merger between Oneness Biotech and Fountain Biopharma makes the pipeline and resources integrated. The pipeline will include a late-stage drug to be launched in global market as well as new drugs in earlier clinical stage in immunology. This merger will strengthen the R&D capability in favor of global collaboration and competition.Read More

  Oneness Biotech has been invited to attend the 16th Annual Global Healthcare Conference by Morgan Stanley. At the meeting, Oneness Biotech will share company’s research progress and business operation to institutional investors.Read More

  Oneness Biotech has submitted the plant-derived new drug application of ON101 (Diabetic foot ulcer drug) to Taiwan Food and Drug Administration on May 14, 2018.Read More

  The second Phase III clinical study was approved by US Food and Drug Administration (FDA) on 3rd March 2018 for the new drug ON101 which is indicated for the chronic diabetic foot ulcer and developed by Oneness Biotech. ON101 is the first new drug in Taiwan with two Phase III clinical studies approved by...Read More

  Published Date:2017-11-10 Original Link:https://www.onenessbio.com/en/news_detail123_1.htm Contact Us繁簡ENRead More